| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Compound of black pepper that boosts bioavailability of curcumin piperine’s bioenhancing function, often more important than piperine’s direct anticancer activity Mechanisms of bioenhancement | Mechanism | Effect | | ----------------------------- | ---------------------------------- | | **↓ CYP3A4, CYP2C9** | Slows metabolic clearance | | **↓ UGT (glucuronidation)** | Increases parent compound exposure | | **↓ P-glycoprotein (ABCB1)** | Improves intracellular retention | | **↑ Intestinal permeability** | Better oral absorption | -Curcumin: ↑ bioavailability ~20–30× -Resveratrol, EGCG, quercetin: ↑ exposure 2–10× Primary pathways: NF-κB, STAT3, PI3K/Akt/mTOR, apoptosis, EMT Direct anticancer potency: modest Bioenhancing value: central and often dominant
|
| Source: |
| Type: |
| COL3A1 - Collagen Type III Alpha 1 Chain / Collagen III Abbreviation: COL3A1, Collagen III, Type III Collagen Type: Extracellular matrix structural protein / fibrillar collagen Function: Collagen III is a fibrillar extracellular-matrix protein composed primarily of COL3A1 chains. It is abundant in connective tissues and commonly associates with type I collagen. Collagen III contributes to tissue tensile strength, extracellular-matrix organization, wound healing, fibrosis, cell adhesion, and mechanical signaling through receptors including integrins and discoidin domain receptors. Cancer: ↑ Frequently increased in tumor-associated extracellular matrix and desmoplastic stroma. Elevated COL3A1/collagen III can reflect cancer-associated fibroblast activation and extracellular-matrix remodeling and may promote tumor-cell adhesion, migration, invasion, metastatic dissemination, and altered mechanotransduction. High COL3A1 expression is associated with aggressive disease and poor prognosis in several cancers, although effects depend on tumor type and matrix organization. |
| 1257- | PI, | Piperlongumine attenuates bile duct ligation-induced liver fibrosis in mice via inhibition of TGF-β1/Smad and EMT pathways |
| - | ex-vivo, | LiverDam, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:133 Target#:1057 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid